文献速递妇科

Tipapkinogen Sovacivec治疗性HPV疫苗在宫颈上皮内瘤变2级和3级中的疗效与安全性:随机对照II期试验及2.5年随访

The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up.
PubMed 文献 · Gynecol Oncol · 2019-04-04

这项随机、双盲、安慰剂对照II期试验纳入宫颈上皮内瘤变2/3级(CIN2/3)女性,按2:1随机分配至Tipapkinogen Sovacivec(TS)疫苗组或安慰剂组。疫苗组CIN2/3完全消退率显著高于安慰剂组(24% vs. 10%,p<0.05),仅CIN3者亦显著更高(21% vs. 0%,p<0.01);疫苗耐受性良好,常见不良事件为注射部位反应。

要点

  • TS疫苗组CIN2/3完全消退率24%,安慰剂组10%(p<0.05)。
  • 仅CIN3者疫苗组完全消退率21%,安慰剂组0%(p<0.01)。
  • 无论基线HPV感染状态,疫苗组病毒DNA清除率均高于安慰剂组(p<0.01)。

核心结论

  • TS疫苗可使三分之一的CIN2/3受试者实现组织学消退,且不依赖于高危HPV型别,并在30个月内总体安全。

研究设计与样本

  • 随机、双盲、安慰剂对照II期试验,18岁及以上确诊CIN2/3女性按2:1比例分配至疫苗组(129例)或安慰剂组(63例)。
  • 主要终点为第6个月行切除治疗时的组织学消退;第3、6个月及此后每6个月至第30个月进行细胞学和高危HPV分型检测。
  • 安全性人群包括所有接受至少一剂研究药物的患者。

主要发现

  • 疫苗组CIN2/3完全消退率显著高于安慰剂组(24% vs. 10%,p<0.05),不限于所检测的13种高危HPV型别。
  • 仅CIN3者疫苗组完全消退率显著高于安慰剂组(21% vs. 0%,p<0.01),不限于高危HPV型别。
  • 无论基线HPV感染状态如何,疫苗组病毒DNA清除率均高于安慰剂组(p<0.01)。
  • 疫苗耐受性良好,最常见不良事件为注射部位反应。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While prophylactic human papillomavirus (HPV) vaccination exists, women are still developing cervical intraepithelial neoplasia (CIN) grade 2 or 3 for which an immunotherapeutic, non-surgical, approach may be effective. The primary aim was to assess the efficacy of tipapkinogen sovacivec (TS) vaccine in achieving histologic resolution of CIN2/3 associated with high risk (HR) HPV types. METHODS: Women 18 years and older who had confirmed CIN2/3 were enrolled in a randomized, double blind, placebo-controlled phase II trial and assigned to drug in a 2:1 ratio (vaccine:placebo). The primary endpoint occurred at month 6 when the excisional therapy was performed; cytology and HR HPV typing were performed at months 3, 6 and every six months through month 30. The safety population included all patients who received at least one dose of study drug. RESULTS: Of the 129 women randomized to vaccine and 63 to placebo, complete resolution was significantly higher in the vaccine group than placebo for CIN 2/3 regardless of the 13 HR HPV types assayed (24% vs. 10%, p < 0.05); as well as for only CIN 3 also regardless of HR HPV type (21% vs. 0%, p < 0.01). Irrespective of baseline HPV infection, viral DNA clearance was higher in the vaccine group compared to placebo (p < 0.01). The vaccine was well tolerated with the most common adverse events being injection site reactions. CONCLUSIONS: The TS vaccine provides histologic clearance of CIN 2/3 irrespective of HR HPV type in one third of subjects and is generally safe through 30 months.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Harper DM, Nieminen P, Donders G, et al. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up. Gynecol Oncol. 2019. PMID: 30955915. doi:10.1016/j.ygyno.2019.03.250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。